Key facts
- It has raised $13.8M; the latest was Later Stage VC ($13.8M) in May 2025.
- Notable investors include Addor Capital, CMG SDIC Fund, Guangzhou Yuexiu Industrial Investment Fund Management, Evonik Venture Capital, Beijing Yidao Capital Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for JLand Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for JLand Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About JLand Biotech
Developer of recombinant collagen products designed to advance cosmetic, medical, and research applications. The company focuses on the design and industrial application of recombinant collagen with bioengineering technologies such as genetic recombination, microbial fermentation, protein separation and purification, providing industries such as cosmetics and food with non-animal sourced collagen products.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2015
- Website
- jlandbiotech.com/
- Ownership
- Privately Held (backing)
JLand Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in JLand Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on JLand Biotech in its N-PORT filings yet. We sweep new filings monthly.